Cervical cancer is the second leading cause of cancer deaths in women worldwide. Human 23 papillomavirus (HPV) is the causative agent of nearly all forms of cervical cancer, which arises 24 upon viral integration into the host genome and concurrent loss of regulatory gene E2. E2 protein 25 regulates viral oncoproteins E6 and E7. Loss of E2 upon viral integration results in unregulated 26 expression and activity of E6 and E7, which promotes carcinogenesis. Previous studies using gene- 27 based delivery show that reintroduction of E2 into cervical cancer cell lines can reduce 28 proliferative capacity and promote apoptosis. However, owing in part to limitations on transfection 29 in vivo, E2 reintroduction has yet to achieve therapeutic usefulness. A promising new approach is 30 protein-based delivery systems utilizing cell-penetrating peptides (CPPs). CPPs readily traverse 31 the plasma membrane and are able to carry with them biomolecular 'cargos' to which they are 32 attached. Though more than two decades of research have been dedicated to their development for 33 delivery of biomolecular therapeutics, the full potential of CPPs has yet to be realized as the field 34 is hindered by the tendency of CPP-linked cargos to be trapped in endosomes as well as having 35 significant off-target potential in vivo. Using a CPP-adaptor system that reversibly binds cargo 36 thereby overcoming the endosomal entrapment that hampers other CPP methods, bioactive E2 37 protein was delivered into living cervical cancer cells, resulting in inhibition of cellular 38 proliferation and promotion of cell death in a time-and dose-dependent manner. The results 39 suggest that this nucleic acid-and virus-free delivery method could be harnessed to develop novel, 40 effective protein therapeutics for treatment of cervical cancer. 41 42 48

